Fulcrum Therapeutics, Inc. (FULC) stock
FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.77+0.09 (+2.45%)
Close on Nov 13, 2026Market cap $287.64MP/E –Yield –
Fulcrum Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Fulcrum Therapeutics's enterprise value was $236.84M on Nov 11, 2026, against $544.87M a year earlier. Over the last 5 years it ranged from $95.15M to $925.40M, with a median of $279.58M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $236.84M | -58.1% |
| 2025 | Dec 31, 2025 | $564.89M | +212.3% |
| 2024 | Dec 31, 2024 | $180.88M | -43.8% |
| 2023 | Dec 29, 2023 | $321.59M | +11.7% |
| 2022 | Dec 30, 2022 | $287.99M | -55.8% |
| 2021 | Dec 31, 2021 | $651.43M | +178.1% |
| 2020 | Dec 31, 2020 | $234.20M | -14.5% |
| 2019 | Dec 31, 2019 | $273.77M | – |
See a number that looks wrong?